Genitourinary cancers require individualized treatment plans based on type, stage, and patient health, utilizing imaging, biopsy, and various therapies. Combining therapies with complementary ...
With the emergence of antibody-drug conjugates, the genitourinary cancers space is rapidly evolving. Dr Ferris addresses ...
When contextualized with the developments across all genitourinary [GU] malignancies, especially renal cell carcinoma and ...
The MarketWatch News Department was not involved in the creation of this content. FCS Physicians Present Novel Clinical Trial Findings in Prostate and Urothelial Cancers at the ASCO 2026 Genitourinary ...
This study leverages CDC National Health Interview Survey data to examine financial distress (FD) among genitourinary (GU) cancer survivors, specifically prostate cancer (PC), kidney cancer (KC), and ...
The evolution of genitourinary cancer treatment includes a shift from monotherapies to combination therapies, improving survival and quality of life. Combining androgen blockers with DNA repair ...
Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen receptor pathway inhibitor. Tanya B. Dorff, MD, medical oncologist and ...
SurvivorNet on MSN
‘Cancer is part of life but so is hope’: When a diagnosis shakes your world, here’s how to take back control with added clarity
Cancer is not an outside invader but a biological process, explains Dr. Alexandra Drakaki, medical director of the ...
Detalimogene voraplasmid is a novel, investigational, pivotal-stage, non-viral genetic medicine designed to mitigate systemic risks and deliver durable efficacy for patients with high-risk NMIBC, ...
Enfortumab vedotin and pembrolizumab combination shows a 49% reduction in mortality risk for advanced bladder cancer compared to chemotherapy. ASCO GU symposium focuses on antibody-drug conjugates, ...
Designing and Validating a Comprehensive Patient-Reported Outcomes Measure for Ambulatory Cancer Settings: The Revised Edmonton Symptom Assessment System for Cancer We retrospectively analyzed ...
FORT MYERS, Fla., Feb. 26, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) advances genitourinary cancer treatment through participation at the global ASCO® 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results